Skip to main content
    R

    Rapport Therapeutics, Inc. Common Stock (RAPP)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $23.76
    -1.06 (-4.27%)

    Market Cap: $1.47B

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Rapport Therapeutics, Inc. Common Stock (RAPP) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Rapport Therapeutics, Inc. Common Stock (RAPP) has a market cap of $1.47B and an enterprise value of $1.40B. Revenue grew 2677.78% over the last 12 months from the 12 months before. It kept -752.35% of revenue as net income over the last 12 months.

    Total Valuation

    Enterprise value is 5.08% below the market cap, as cash exceeds debt.

    Market Cap$1.47B
    Enterprise Value$1.40B
    Latest price (Nov 17, 2026)$23.76

    Key Dates

    The next earnings report is expected on Mar 8, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 8, 2027 (expected)
    Last Earnings DateNov 4, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.62% in the quarter ended Sep 30, 2026 and grew 17.07% a year over 2 years.

    Shares Outstanding47.77M
    Shares Change (YoY)+25.94%
    Shares Change (QoQ)+0.62%
    Share Count Growth (2Y CAGR)+17.07%

    Valuation Ratios

    Sales and book value multiples are 56.7x and 2.9x.

    P/S Ratio56.7x
    Forward P/S73.5x
    P/B Ratio2.9x

    Price Statistics

    The stock is down 2.50% over 52 weeks and trades 23.50% below its 50-day average.

    Beta (1Y)1.34
    52-Week Change-2.50%
    1-Month Change-16.92%
    3-Month Change-51.58%
    6-Month Change-30.87%
    Total Return (1Y)-2.50%
    Return vs SPY (1Y)-17.72%
    Max Drawdown (1Y)-57.14%
    Max Drawdown (3Y)-75.54%
    Sharpe Ratio (1Y)-0.10
    Correlation with SPY (1Y)0.29
    50-Day Average$31.06
    200-Day Average$35.56
    52-Week Range$22.06 to $52.93
    RSI (14 Days)38.5
    Average Volume (20 Days)1.26M

    Price chart

    Financial Position

    Current assets cover 20.07x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio20.07x
    Quick Ratio20.07x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -38.46% and return on assets is -35.95% over the last 12 months.

    Return on Equity (ROE)-38.46%
    Return on Assets (ROA)-35.95%
    Asset Turnover0.04x
    Receivables Turnover86.21x

    Scores

    RAPP has an Altman Z-Score of 23.54, in the safe zone above 2.99, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Altman Z-Score23.54
    Altman Z ZoneSafe
    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $20.00M over the last 12 months.

    Revenue$20.00M
    Revenue Growth (YoY)+2677.78%
    Gross Profit$19.73M
    Operating Income-$167.62M
    Pretax Income-$150.47M
    Net Income-$150.47M
    Reported EPS (TTM)-$3.17

    Trailing 12 months through Sep 30, 2026.

    Balance Sheet

    Shareholder equity funds 93.46% of the $418.56M in total assets.

    Cash and Equivalents$74.75M
    Total Debt$0
    Net Cash$74.75M
    Net Cash Per Share$1.56
    Working Capital$387.08M
    Shareholder Equity$391.19M
    Book Value Per Share$8.19
    Total Assets$418.56M
    Total Liabilities$27.37M

    Balance sheet as of Sep 30, 2026.

    Cash Flow

    Operating Cash Flow-$120.85M
    FCF Per Share-$2.10
    Depreciation and Amortization$3.39M

    Trailing 12 months through Sep 30, 2026.

    Margins

    The operating margin is -838.08%.

    Gross Margin98.67%
    Operating Margin-838.08%
    Pretax Margin-752.35%
    Net Margin-752.35%

    Peer Position

    Against 7 similar companies, RAPP has the 4th highest P/S.

    P/S Ratio56.7x vs 21.6x median
    Revenue Growth (Trailing 4 Quarters, YoY)+2677.78% vs -59.47% median

    Competitors compared

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About RAPP

    What is RAPP's market cap?

    Rapport Therapeutics, Inc. Common Stock has a market cap of $1.47B. Its enterprise value, which adds debt and subtracts cash, is $1.40B.

    How many shares of RAPP are outstanding?

    Rapport Therapeutics, Inc. Common Stock has 47.77M shares outstanding. The count is up 25.94% from a year earlier.

    Does RAPP pay a dividend?

    No. Rapport Therapeutics, Inc. Common Stock does not pay a dividend.

    How much debt does RAPP have?

    Rapport Therapeutics, Inc. Common Stock has $0 of total debt and $74.75M of cash and equivalents, a net cash position of $74.75M.